Costs and medical care consequences associated with the diagnosis of peripheral arterial disease

PharmacoEconomics

Volumn 23, Issue 7, 2005, Pages 733-742

  Migliaccio Walle, Kristen ^a   Caro, J Jaime ^a,b   Ishak, Khajak J ^c   O'Brien, Judith A ^a  

^a CARO RESEARCH INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c Caro Research Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTERY DISEASE; ARTICLE; CANADA; CONTROLLED STUDY; COST OF ILLNESS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART INFARCTION; HOSPITAL COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL FEE; PHYSICIAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RESOURCE ALLOCATION; RETROSPECTIVE STUDY;

AGED; CANADA; COHORT STUDIES; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 22344433300     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523070-00007     Document Type: Article

References (26)

1. Criqui MH. Systematic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease. Am J Cardiol 2001; 88 Suppl. 2: 43-7
2. Criqui MH. Peripheral arterial disease: epidemiological aspects. Vasc Med 2001; 6 Suppl. 1: 3-7
3. Stoffers HE, Rinkens RP, Kester AD, et al. The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. Int J Epidemiol 1996; 25: 282-90
4. Hooi J. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Scand J Prim Health Care 1998; 16: 177-82
5. Weitz JI, Byrne J, Clagett P, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996; 94: 3026-49
6. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-24
7. Criqui MH. Systematic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease. Am J Cardiol 2001; 88 Suppl. 2: 43-7
8. Weitz JI, Byrne J, Clagett P, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996; 94: 3026-49
9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
10. Howell MA, Colgan MP, Seeger RW, et al. Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study. J Vasc Surg 1989; 9: 691-7
11. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-6
12. Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002; 33: 901-6
13. Bowlin SJ, Medalie JH, Flocke SA, et al. Intermittent claudication in 8343 men and 21-year specific mortality follow-up. Ann Epidemiol 1997; 7: 180-7
14. Murabito JM, D'Agostino RB, Silbershatz H, et al. Intermittent claudication: a risk profile from The Framingham Heart Study. Circulation 1997; 96: 44-9
15. Brown JB, Delea TE, Nichols GA, et al. Use of oral antithrombotic agents among health maintenance organization members with atherosclerotic cardiovascular disease. Arch Intern Med 2002; 162: 193-9
16. Anand SS, Kundi A, Eikelboom J, et al. Low rates of preventive practices in patients with peripheral arterial disease. Can J Cardiol 1999; 15: 1259-63
17. Zachry WM, Wilson JP, Lawson KA, et al. Procedure costs and outcomes associated with pharmacologic management of peripheral arterial disease in the Department of Defense. Clin Ther 1999; 21: 1358-69
18. McDermott MM, Hahn EA, Greenland P, et al. Atherosclerotic risk factor reduction in peripheral arterial disease. J Gen Intern Med 2002; 17: 895-904
19. Caro JJ, Huybrechts KF, Klittich WS, et al. Allocating funds for the cardiovascular disease prevention in light of the NCEP ATP III guidelines. Am J Manag Care 2003; 9: 477-89
20. Malcolm E, Downey W, Strand LM, et al. Saskatchewan Health's linkable data bases and pharmacoepidemiology. Post Marketing Surveillance 1993; 6: 175-264
21. Caro JJ, Migliaccio-Walle K, on behalf of the CAPRA Study Group. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. Am J Med 1999; 107: 568-72
22. Stergachis A, Sheingold S, Luce BR, et al. Medical care and cost outcomes after pentoxifylline treatment for peripheral arterial disease. Arch Intern Med 1992; 152: 1220-4
23. The Ontario Case Costing Project. The Ontario Case Costing Program Database 1995-96. Ottawa (ON): Ontario Ministry of Health and Ontario Hospital Association, 1996
24. The Ontario Case Costing Project. FY 1999/2000 Typical Cases file [online]. Available from URL: http://www. occp.com [Accessed 2002 Feb 28]
25. Alberta Health and Wellness. Health Resourcing Branch: Health Costing in Alberta, Annual Report, 1999 [online]. Available from URL: http://www.health. gov.ab.ca/public/doc-ument/ar99-00/ [Accessed 2002 Feb 28]
26. Stegman MS, Aaron WS, eds. St. Anthony's ICD-9-CM Code Book. Reston (VA): St. Anthony's Publishing, Inc., 1995